latest update:
[TrialBase DB]

trial summary · NCT07594067

TCR1188-ABC Cells in KRAS-mutated Cancers

Phase I, Open-Label Study of Autologous Mutant KRAS and ILT4-Redirected T-cell Receptor Cells (TCR1188-ABC)

Trial record from the TrialBase DB dataset, status RECRUITING, condition Cholangiocarcinoma, sponsored by University of Pennsylvania. Facts below are exported values from the current release, not inferred or edited prose.

registry NCT07594067phase PHASE1enrollment 30start 2026-12

Summary

The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.

This is a Phase I, open-label dose finding study to assess the safety, manufacturing feasibility, and preliminary efficacy of TCR1188-ABC cells in patients with KRAS-mutated cancers. Initially, patients with KRAS G12V mutation positive metastatic pancreatic adenocarcinoma, cholangiocarcinoma, colorectal cancer, or non-small cell lung cancer (NSCLC) will be targeted for participation. Up to 4 total dose levels will be evaluated using a 3+3 dose escalation design.

Source record: https://clinicaltrials.gov/study/NCT07594067

Facts

registry idNCT07594067
primary registryclinicaltrials-gov
recruitment statusRECRUITING
phasePHASE1
study typeINTERVENTIONAL
lead conditionCholangiocarcinoma
sponsorUniversity of Pennsylvania
sponsor classOTHER
enrollment30
start date2026-12
primary completion2042-11
completion2042-11
results postednot reported

Conditions

  • Cholangiocarcinoma
  • Colorectal Cancer
  • Non-Small Cell Lung Cancer
  • Pancreatic Adenocarcinoma

Interventions

  • TCR1188-ABC cells
  • Fludarabine + Cyclophosphamide combination
  • Tocilizumab

Countries

  • United States

Intervention types: BIOLOGICAL, DRUG

Work with this record